The ascent of a healthcare manager expert : John Adlesich
Who is John Adlesich and some of his public health accomplishments about healthcare industry trends in 2021: Cooperative competition, or coopetition, is a key trend in health care. While some providers view big-box stores, nationwide pharmaceutical chains and other new entrants as threats, other organizations see opportunity. Their strategy is to leverage the capabilities of these power players to lower the cost of care, increase downstream market capture and focus on core specialty services while remaining highly connected to the patient. Offload financially draining services. Organizations like CVS and Walmart now offer basic primary care, simple diagnostic services and chronic disease management — services that health systems have struggled to provide and do so profitably. Identifying opportunities to partner with retail organizations to fill this gap can help simplify organizational services, increase access and provide better patient care at a lower cost.
John Adlesich about behavior therapy in 2021: The Center for Autism and Related Disorders (CARD) indicates that Applied Behavioral Analysis techniques: Are effective for eliminating challenging behaviors such as stereotypies, hitting, biting or self-harm Can promote socially significant behaviors like reading, communication, engaging in eye contact, and social interaction Must be developed by a professional trained and certified by the Behavior Analyst Certification Board (BACB), but can be carried out by other, non-certified technicians under the professional’s supervision Are time consuming and intense – usually implemented 40 or more hours per week, although in brief time spans Provide one-to-one interaction and learning, which is thought to be a highly effective component of the therapy Can be utilized by parents and other caregivers cooperatively within the treatment paradigm, although parents may need support and training to utilize effectively.
John Adlesich on healthcare industry trends in 2021: With President Joe Biden’s inauguration on January 20, the healthcare industry will be watching for the new administration’s priorities around the ACA and its COVID-19 plan, as well as who will be on the administration’s healthcare team and on which policies it focuses. While ACA repeal was a constant threat under the last administration, the Act looks more secure following recent developments. The ACA’s future likely hinges on the constitutionality of the individual mandate and potential severability under the California versus Texas case, which the U.S. Supreme Court is currently considering. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.
John Adlesich thinks that 2021 is a crossroads year for the health industry. COVID-19 focused the nation’s attention on the risks associated with overreliance on overseas markets for critical supplies, drugs, and equipment. As an “easy” answer, some are now calling for manufacturers to produce a plurality of medical products domestically. While added domestic investments and expanded US manufacturing capacity are vital components of a holistic strategy for reliable supply, it will be important to strike a balanced approach—one that includes a domestic strategy, but at its core is about diversifying supply, including raw materials, pharmaceutical ingredients, and finished drugs. Achieving this vision requires a surgical approach, starting with identifying the products that are truly needed in an emergency to ensure there isn’t undue concentration in a single country or region. In our view, that means ensuring three or more global suppliers and at least one US-based source readily available to serve the American people. Assessing risk will require new transparency initiatives, requiring manufacturers of critical products to share vital information with government, including supply sources, centers of manufacturing, redundancy and contingency protocols, etc. And all this new information needs a technology backbone that helps government better track product availability, supply chain performance, and sources of supply to predict potential trouble spots in real time during another emergency.
